FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
|Poll|August 14, 2015
Mini Quiz: Cultural Diversity and the Young Patient
What are the benefits of exploring cultural issues with a young patient and family before proceeding with treatment?
Advertisement
Which of the following does NOT necessarily occur after exploring cultural issues with a young patient?
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Public health professional Shambrekia Wise and her daughter Sandy discuss the origins of their travel-themed book series and its relevance to clinicians treating diverse young patients.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
Brenipatide for Alcohol Use Disorder: Emerging Findings
3
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5